<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01967667</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00056458</org_study_id>
    <nct_id>NCT01967667</nct_id>
  </id_info>
  <brief_title>Biological Evaluation of Dietary Supplement Liposomal Glutathione</brief_title>
  <official_title>Biological Evaluation of Dietary Supplement Liposomal Glutathione</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low levels of antioxidant molecules such as glutathione have been found in people with a&#xD;
      diagnosis of schizophrenia. However, oral glutathione is not well absorbed because the&#xD;
      compound is mostly broken down in the gastrointestinal system. Liposomes are tiny droplets of&#xD;
      oil particles that encapsulate and protect the glutathione. In this study we will evaluate a&#xD;
      liposomal formulation of glutathione for tolerability and to examine if this formulation&#xD;
      serves the function of increasing glutathione in the brain and body.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Additional information about this dietary supplement:&#xD;
&#xD;
        -  Glutathione is an antioxidant naturally produced in our body. Glutathione protects the&#xD;
           brain and other organs from oxidative stress.&#xD;
&#xD;
        -  Low glutathione is associated with high oxidative stress, which has been linked to aging&#xD;
           and many illnesses. Schizophrenia is a mental illness that doctors still do not fully&#xD;
           understand. Individuals with schizophrenia often have low levels of glutathione.&#xD;
&#xD;
        -  Glutathione can be supplied through dietary supplement. However, if taken plainly, it&#xD;
           easily breaks down in our gut.&#xD;
&#xD;
        -  Scientists have now found a way to wrap glutathione in tiny drops of oil particles&#xD;
           called liposomes. That way, the gut cannot break it down so it is absorbed into our&#xD;
           body. Once inside the body, our cells can take in the liposomes and use the glutathione&#xD;
           to reduce oxidative stress.&#xD;
&#xD;
        -  Liposome-wrapped glutathione is not a drug or medicine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">February 2021</completion_date>
  <primary_completion_date type="Actual">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glutathione levels</measure>
    <time_frame>Baseline and 3 weeks</time_frame>
    <description>Change of glutathione levels from baseline to following 3 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>oxidative stress biomarker</measure>
    <time_frame>baseline and 3 weeks</time_frame>
    <description>blood levels of lipid peroxidation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory marker</measure>
    <time_frame>baseline and 3 weeks</time_frame>
    <description>Blood levels of cytokines as biomarkers of inflammation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>BPRS</measure>
    <time_frame>Baseline and 3 weeks</time_frame>
    <description>Change in brief psychiatric rating scale scores from baseline to end of treatment phase and end of placebo phase.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Baseline and 3 weeks</time_frame>
    <description>side-effects checklist</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Liposomal glutathione</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose steps</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>dose steps</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Liposomal glutathione</intervention_name>
    <description>Escalating dose steps</description>
    <arm_group_label>Liposomal glutathione</arm_group_label>
    <other_name>ReadiSorb glutathione</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>escalating dose steps</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Readisorb solution without glutathione</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age range: 18-60&#xD;
&#xD;
          -  DSM diagnosis of schizophrenia spectrum disorder, including schizophrenia,&#xD;
             schizoaffective disorder, and schizophreniform disorder&#xD;
&#xD;
          -  Ability to give written informed consent (Evaluation to Sign Consent score 10 or&#xD;
             greater)&#xD;
&#xD;
          -  Clinically stable with no change in antipsychotic medications nor significant increase&#xD;
             of daily dose for 2 weeks prior to enrollment&#xD;
&#xD;
          -  Low baseline blood glutathione level (GSH &lt; 890 umol/l)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of major medical illness including, but not limited to, history of heart&#xD;
             attack, stroke, TIA (transient ischemic attack)&#xD;
&#xD;
          -  History of organic brain disorders that may affect neurophysiological measurements,&#xD;
             including seizure disorder, brain tumor, head injury with evidence of significant&#xD;
             cognitive deterioration&#xD;
&#xD;
          -  DSM diagnosis of substance dependence within 6 months except nicotine and marijuana,&#xD;
             or substance abuse in past month&#xD;
&#xD;
          -  Uncontrolled blood pressure (persistent systolic above 165 or diastolic above 100)&#xD;
&#xD;
          -  On medication containing cholesterol absorption inhibitor such as ezetimibe (Brand&#xD;
             names Zetia, Ezetrol, Vytorin, and Inegy)&#xD;
&#xD;
          -  Women who have positive urine pregnancy tests&#xD;
&#xD;
          -  Women who plan to become pregnant, or are breastfeeding&#xD;
&#xD;
          -  Unable to undergo MRI scanning due to metallic devices or objects or claustrophobia&#xD;
&#xD;
          -  Already taking dietary antioxidant supplements such as n-acetylcysteine or fish oil on&#xD;
             regular basis (more than twice a week) in the last 3 months&#xD;
&#xD;
          -  History of allergy to soy or soy products&#xD;
&#xD;
          -  Hyperlipidemia (baseline LDL &gt; 1.5 x upper limit of normal)&#xD;
&#xD;
          -  Liver impairment (baseline AST or ALT &gt; 2.0 x upper limit of normal)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>L. Elliot Hong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maryland Psychiatric Research Center</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 17, 2013</study_first_submitted>
  <study_first_submitted_qc>October 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2013</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>MPRC</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

